{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-034583","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.530172+00:00","generated_at":"2026-06-03T15:15:30.172954+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve equity plan increase at 2024 annual meeting","bullets":["All 11 director nominees were re-elected; quorum of 5,736,015 shares (54.31%) represented.","Ratified WWC P.C. CPA as independent auditor for FY2024 with 5,449,292 votes for.","Approved issuance of shares exceeding 20% of outstanding stock to Lind Global Fund II under convertible notes/warrants.","Increased Amended 2016 Equity Incentive Plan to 1,283,002 shares (12.15% of outstanding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-034583","json":"https://secwatch.observer/filing/0001213900-24-034583.json","markdown":"https://secwatch.observer/filing/0001213900-24-034583.md","text":"https://secwatch.observer/filing/0001213900-24-034583.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024034583/0001213900-24-034583-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024034583/ea020408501-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T15:15:30.172954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26df2c9d2e863986f9d452b8225df4246d49e259","claim":"ABVC BIOPHARMA, INC. shareholders approved To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying convertible notes and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement dated February 23, 2023, and certain Securities Purchase Agr at the 2024-04-16 meeting.","evidence_excerpt":"For Against Abstain 4,497,446 77,101 11,553","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024034583/0001213900-24-034583-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-16"}],"fact_type":"shareholder_vote"},{"claim_id":"34b68a03d9a44db79bf823d3cdbe3bbbe5836625","claim":"ABVC BIOPHARMA, INC. shareholders approved To approve an increase in the company’s Amended and Restated 2016 Equity Incentive Plan up to a maximum of 15% of current issued and outstanding shares at the 2024-04-16 meeting.","evidence_excerpt":"For Against Abstain 4,483,481 96,204 6,415","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024034583/0001213900-24-034583-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-16"}],"fact_type":"shareholder_vote"},{"claim_id":"c602d3a3f7ee90bc8e5188d9250ee60c1b9d2791","claim":"ABVC BIOPHARMA, INC. shareholders approved To ratify the appointment of WWC P.C. CPA as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-04-16 meeting.","evidence_excerpt":"For Against Abstain 5,449,292 123,503 163,220","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024034583/0001213900-24-034583-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-16"}],"fact_type":"shareholder_vote"},{"claim_id":"f52d315215045f34f1d69497f3fa3b71f5a7d6f5","claim":"ABVC BIOPHARMA, INC. shareholders approved To re-elect 11 directors to the Company’s board of directors at the 2024-04-16 meeting.","evidence_excerpt":"Eugene Jiang 4,542,439 0 43,661","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024034583/0001213900-24-034583-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}